Department of Computer Application, Babu Banarasi Das University, Lucknow, India.
Department of Computer Science and Engineering, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.
Sci Rep. 2023 Apr 29;13(1):7051. doi: 10.1038/s41598-023-32850-8.
Malignant cancer angiogenesis has historically attracted enormous scientific attention. Although angiogenesis is requisite for a child's development and conducive to tissue homeostasis, it is deleterious when cancer lurks. Today, anti-angiogenic biomolecular receptor tyrosine kinase inhibitors (RTKIs) to target angiogenesis have been prolific in treating various carcinomas. Angiogenesis is a pivotal component in malignant transformation, oncogenesis, and metastasis that can be activated by a multiplicity of factors (e.g., VEGF (Vascular endothelial growth factor), (FGF) Fibroblast growth factor, (PDGF) Platelet-derived growth factor and others). The advent of RTKIs, which primarily target members of the VEGFR (VEGF Receptor) family of angiogenic receptors has greatly ameliorated the outlook for some cancer forms, including hepatocellular carcinoma, malignant tumors, and gastrointestinal carcinoma. Cancer therapeutics have evolved steadily with active metabolites and strong multi-targeted RTK inhibitors such as E7080, CHIR-258, SU 5402, etc. This research intends to determine the efficacious anti-angiogenesis inhibitors and rank them by using the Preference Ranking Organization Method for Enrichment Evaluation (PROMETHEE- II) decision-making algorithm. The PROMETHEE-II approach assesses the influence of growth factors (GFs) in relation to the anti-angiogenesis inhibitors. Due to their capacity to cope with the frequently present vagueness while ranking alternatives, fuzzy models constitute the most suitable tools for producing results for analyzing qualitative information. This research's quantitative methodology focuses on ranking the inhibitors according to their significance concerning criteria. The evaluation findings indicate the most efficacious and idle alternative for inhibiting angiogenesis in cancer.
恶性癌症血管生成在历史上引起了极大的科学关注。虽然血管生成对于儿童的发育和组织平衡是必要的，但当癌症潜伏时，它是有害的。如今，针对血管生成的抗血管生物分子受体酪氨酸激酶抑制剂（RTKIs）在治疗各种癌症方面已经非常丰富。血管生成是恶性转化、肿瘤发生和转移的关键组成部分，可以被多种因素激活（例如，VEGF（血管内皮生长因子）、FGF（成纤维细胞生长因子）、PDGF（血小板衍生生长因子）等）。RTKIs 的出现，主要针对血管生成的血管内皮生长因子受体（VEGFR）家族成员，极大地改善了一些癌症形式的前景，包括肝细胞癌、恶性肿瘤和胃肠道癌。癌症治疗剂随着活性代谢物和强多靶点 RTK 抑制剂（如 E7080、CHIR-258、SU 5402 等）的出现而不断发展。本研究旨在确定有效的抗血管生成抑制剂，并使用偏好排序组织 enrichment 评估方法（PROMETHEE-II）决策算法对其进行排名。PROMETHEE-II 方法评估了生长因子（GFs）与抗血管生成抑制剂相关的影响。由于它们在对替代品进行排名时具有处理模糊性的能力，因此模糊模型是分析定性信息产生结果的最合适工具。本研究的定量方法侧重于根据标准对抑制剂进行排名。评估结果表明了在癌症中抑制血管生成最有效和最有效的替代品。
